1. van de Putte LBA. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63: 508–516. doi:10.1136/ard.2003.013052
2. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015;372: 311–319. doi:10.1056/NEJMoa1411087
3. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. N Engl J Med. 2015;372: 2018–2028. doi:10.1056/NEJMoa1501824
4. Kaplon H, Reichert JM. Antibodies to watch in 2021. MAbs. 2021;13: 1860476. doi:10.1080/19420862.2020.1860476
5. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med. 2010;363: 1812– 1821. doi:10.1056/NEJMoa1002965
6. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367: 1783–1791. doi:10.1056/NEJMoa1209124
7. Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382: 610–621. doi:10.1056/NEJMoa1914510
8. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384: 1529–1541. doi:10.1056/NEJMoa2028485
9. Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, et al. Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med. 2016;374: 2044– 2053. doi:10.1056/NEJMoa1511769
10. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera J-M, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376: 836–847. doi:10.1056/NEJMoa1609783
11. Owens B. Faster, deeper, smaller—the rise of antibody-like scaffolds. Nat Biotechnol. 2017;35: 602–603. doi:10.1038/nbt0717-602
12. Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, Nygren P-Å. Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain. Nat Biotechnol. 1997;15: 772–777. doi:10.1038/nbt0897-772
13. Beste G, Schmidt FS, Stibora T, Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci. 1999;96: 1898–1903. doi:10.1073/pnas.96.5.1898
14. Stumpp MT, Forrer P, Binz HK, Plückthun A. Designing Repeat Proteins: Modular Leucine-rich Repeat Protein Libraries Based on the Mammalian Ribonuclease Inhibitor Family. J Mol Biol. 2003;332: 471–487. doi:10.1016/S0022-2836(03)00897-0
15. Gebauer M, Skerra A. Engineered Protein Scaffolds as Next-Generation Therapeutics. Annu Rev Pharmacol Toxicol. 2020;60: 391–415. doi:10.1146/annurev-pharmtox-010818-021118
16. Nishimiya D, Kawaguchi Y, Kodama S, Nasu H, Yano H, Yamaguchi A, et al. A protein scaffold, engineered SPINK2, for generation of inhibitors with high affinity and specificity against target proteases. Sci Rep. 2019;9: 11436. doi:10.1038/s41598-019-47615-5
17. Chen T, Lee T-R, Liang W-G, Chang W-SW, Lyu P-C. Identification of trypsin-inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor. Proteins Struct Funct Bioinforma. 2009;77: 209–219. doi:10.1002/prot.22432
18. Hu J, Van den Steen PE, Sang Q-XA, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007;6: 480–98. doi:10.1038/nrd2308
19. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278: 16–27. doi:10.1111/j.1742- 4658.2010.07919.x
20. Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, et al. Matrix metalloproteinases. Curr Med Chem. 2010;17: 3751–3768. doi:10.2174/092986710793213724
21. Elkins PA, Yen SH, Smith WW, Janson CA, D’Alessio KJ, McQueney MS, et al. Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr Sect D Biol Crystallogr. 2002;58: 1182–1192. doi:10.1107/S0907444902007849
22. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem. 1992;267: 3581–3584.
23. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem. 1992;267: 21712–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/1400481
24. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-ras oncogene- transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem. 1988;263: 6579–6587.
25. Murphy G, Ward R, Hembry RM, Reynolds JJ, Kuhnt K, Tryggvasont K. Characterization of gelatinase from pig polymorphonuclear leucocytes. Biochem J 258, 463-472. 1989;258: 463–472.
26. Vandooren J, Van Den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade. Crit Rev Biochem Mol Biol. 2013;48: 222–272. doi:10.3109/10409238.2013.770819
27. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol. 2001;19: 661–667. doi:10.1038/90273
28. Maskos K. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors. Biochimie. 2005;87: 249–263. doi:10.1016/j.biochi.2004.11.019
29. Steffensen B, Wallon MU, Christopher OM. Extracellular Matrix Binding Properties of Recombinant Fibronectin Type II-like Modules of Human 72-kDa Gelatinase/Type IV Collagenase. J Biol Chem. 1995;270: 11555–11566.
30. O’Farrell TJ, Pourmotabbed T. The fibronectin-like domain is required for the type V and XI collagenolytic activity of gelatinase B. Arch Biochem Biophys. 1998;354: 24–30. doi:10.1006/abbi.1998.0662
31. Xu X, Chen Z, Wang Y, Yamada Y, Steffensen B. Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem J. 2005;392: 127–134. doi:10.1042/BJ20050650
32. Mondal S, Adhikari N, Banerjee S, Amin SA, Jha T. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview. Eur J Med Chem. 2020;194: 112260. doi:10.1016/j.ejmech.2020.112260
33. Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? Nat Rev Drug Discov. 2014;13: 904–927. doi:10.1038/nrd4390
34. Sela-Passwell N, Kikkeri R, Dym O, Rozenberg H, Margalit R, Arad-Yellin R, et al. Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential. Nat Med. 2012;18: 143–147. doi:10.1038/nm.2582
35. Gomis-Rüth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997;389: 77–81. doi:10.1038/37995
36. Sharabi O, Shirian J, Grossman M, Lebendiker M, Sagi I, Shifman J. Affinity- and specificity- enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPs. PLoS One. 2014;9. doi:10.1371/journal.pone.0093712
37. Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, et al. Development of high affinity and high specificity inhibitors of matrix metalloproteinase 14 through computational design and directed evolution. J Biol Chem. 2017;292: 3481–3495. doi:10.1074/jbc.M116.756718
38. Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, et al. Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14. FEBS Lett. 2018;592: 1122–1134. doi:10.1002/1873-3468.13016
39. Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. Biochim Biophys Acta - Mol Cell Res. 2017;1864: 1927– 1939. doi:10.1016/j.bbamcr.2017.06.009
40. Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, et al. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis. 1999;17: 177–81. doi:10.1023/a:1006603723759
41. Rosenberg GA. Matrix metalloproteinases in neuroinflammation. Glia. 2002;39: 279–91. doi:10.1002/glia.10108
42. Weiss N, Miller F, Cazaubon S, Couraud P-O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788: 842–57. doi:10.1016/j.bbamem.2008.10.022
43. Lin C, Wu W, Lu H, Li W, Bao Z, Wang Y, et al. MMP-9 Inhibitor GM6001 Prevents the Development of ssTBI-Induced Parkinson’s Disease via the Autophagy Pathway. Cell Mol Neurobiol. 2020. doi:10.1007/s10571-020-00933-z
44. Kaplan A, Spiller KJ, Towne C, Kanning KC, Choe GT, Geber A, et al. Neuronal matrix metalloproteinase-9 is a determinant of selective neurodegeneration. Neuron. 2014;81: 333–48. doi:10.1016/j.neuron.2013.12.009
45. Mishiro K, Ishiguro M, Suzuki Y, Tsuruma K, Shimazawa M, Hara H. A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience. 2012;205: 39–48. doi:10.1016/j.neuroscience.2011.12.042
46. Ishida Y, Kuninaka Y, Nosaka M, Kimura A, Taruya A, Furuta M, et al. Prevention of CaCl2- induced aortic inflammation and subsequent aneurysm formation by the CCL3-CCR5 axis. Nat Commun. 2020;11: 5994. doi:10.1038/s41467-020-19763-0
47. Beckett D, Kovaleva E, Schatz PJ. A minimal peptide substrate in biotin holoenzyme synthetase- catalyzed biotinylation. Protein Sci. 1999;8: 921–929. doi:10.1110/ps.8.4.921
48. Rosenblum G, Van den Steen PE, Cohen SR, Grossmann JG, Frenkel J, Sertchook R, et al. Insights into the Structure and Domain Flexibility of Full-Length Pro-Matrix Metalloproteinase- 9/Gelatinase B. Structure. 2007;15: 1227–1236. doi:10.1016/j.str.2007.07.019
49. O’Connell JP, Willenbrock F, Docherty AJ, Eaton D, Murphy G. Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B. J Biol Chem. 1994;269: 14967–73. Available: http://www.ncbi.nlm.nih.gov/pubmed/8195131
50. Bradbury AR., Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004;290: 29–49. doi:10.1016/j.jim.2004.04.007
51. Nam DH, Rodriguez C, Remacle AG, Strongin AY, Ge X. Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries. Proc Natl Acad Sci U S A. 2016;113: 14970–14975. doi:10.1073/pnas.1609375114
52. Morrison JF. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta. 1969;185: 269–286. doi:10.1016/0005-2744(69)90420-3
53. Johnson K, Goody R. The Original Michaelis Constant. Biochemistry. 2012;50: 8264–8269. doi:10.1021/bi201284u.The
54. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem. 2001;276: 20572–8. doi:10.1074/jbc.M100900200
55. Appleby TC, Greenstein AE, Hung M, Liclican A, Velasquez M, Villasenor AG, et al. Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9. J Biol Chem. 2017;292: 6810–6820. doi:10.1074/jbc.M116.760579
56. Marshall DC, Lyman SK, McCauley S, Kovalenko M, Spangler R, Liu C, et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS One. 2015;10. doi:10.1371/journal.pone.0127063
57. Goffin L, Fagagnini S, Vicari A, Mamie C, Melhem H, Weder B, et al. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment of Inflammatory Bowel Disease Complications with Fibrosis. Inflamm Bowel Dis. 2016;22: 2041–2057. doi:10.1097/MIB.0000000000000863
58. Roeb E, Behrmann I, Grötzinger J, Breuer B, Matern S. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J. 2000;14: 1671–1673. doi:10.1096/fj.99-0947fje
59. Roderfeld M, Weiskirchen R, Wagner S, Berres M-L, Henkel C, Grötzinger J, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J. 2006;20: 444–54. doi:10.1096/fj.05-4828com
60. Rowsell S, Hawtin P, Minshull CA, Jepson H, Brockbank SM V, Barratt DG, et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J Mol Biol. 2002;319: 173–81. doi:10.1016/S0022-2836(02)00262-0
61. Cheng M, De B, Pikul S, Almstead NG, Natchus MG, Anastasio M V, et al. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J Med Chem. 2000;43: 369–80. doi:10.1021/jm990366q
62. Higashi S, Miyazaki K. Identification of amino acid residues of the matrix metalloproteinase-2 essential for its selective inhibition by β-amyloid precursor protein-derived inhibitor. J Biol Chem. 2008;283: 10068–10078. doi:10.1074/jbc.M709509200
63. Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S. Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein- derived inhibitor. J Biol Chem. 2011;286: 33236–33243. doi:10.1074/jbc.M111.264176
64. Tranchant I, Vera L, Czarny B, Amoura M, Cassar E, Beau F, et al. Halogen bonding controls selectivity of FRET substrate probes for MMP-9. Chem Biol. 2014;21: 408–413. doi:10.1016/j.chembiol.2014.01.008
65. Tallant C, Marrero A, Gomis-Rüth FX. Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim Biophys Acta - Mol Cell Res. 2010;1803: 20–28. doi:10.1016/j.bbamcr.2009.04.003
66. Gomis-Rüth FX. Structural aspects of the metzincin clan of metalloendopeptidases. Mol Biotechnol. 2003;24: 157–202. doi:10.1385/MB:24:2:157
67. Santamaria S, de Groot R. Monoclonal antibodies against metzincin targets. Br J Pharmacol. 2019;176: 52–66. doi:10.1111/bph.14186
68. Desmyter A, Transue TR, Ghahroudi MA, Dao Thi M-H, Poortmans F, Hamers R, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Mol Biol. 1996;3: 803–811. doi:10.1038/nsb0996-803
69. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci. 2006;103: 4586–4591. doi:10.1073/pnas.0505379103
70. Brams M, Govaerts C, Kambara K, Price KL, Spurny R, Gharpure A, et al. Modulation of the Erwinia ligand-gated ion channel (ELIC) and the 5-HT3 receptor via a common vestibule site. Elife. 2020;9. doi:10.7554/eLife.51511
71. Razai AS, Eckelman BP, Salvesen GS. Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody. J Biol Chem. 2020;295: 2464–2472. doi:10.1074/jbc.RA119.011712